Vermont Pharmaceutical Marketer Price Disclosure

Background

In accordance with Vermont law 18 V.S.A. § 4633, marketers of certain pharmaceutical products are required to disclose to Vermont doctors and other prescribers Average Wholesale Price ("AWP") information for drugs they market as well as the AWPs of other drugs in the same therapeutic class.

Disclaimers:

Avanir does not set or suggest the AWP information listed on the disclosure forms. The AWP information identified on the disclosure forms is based on third party published data and may not be reflective of prices actually charged to or paid for by any customer.

The disclosure forms and statements on those forms are required by the Vermont Attorney General's "Guide to Vermont's Pharmaceutical Marketer Price Disclosure".

The forms use the American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification to identify the "Other Products" listed in the same AHFS class as the "Marketed product". This does not imply that the "Other Products" listed on the disclosure forms are therapeutically equivalent or interchangeable with the Avanir Marketed Product. The AHFS version used for the current forms is the 2017 edition.

NUEDEXTA Short Form
NUEDEXTA Long Form

Further Information:

If you have any questions concerning this statute, please contact the Vermont Attorney General’s office:

Attorney General's Office
109 State Street
Montpelier, VT 05609-1001
Phone: (802) 828-3171
Email: atginfo@atg.state.vt.us